KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Net Cash Flow (2020 - 2026)

AbCellera Biologics filings provide 7 years of Net Cash Flow readings, the most recent being -$51.4 million for Q1 2026.

  • Quarterly Net Cash Flow fell 2286.81% to -$51.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$83.2 million through Mar 2026, down 325.3% year-over-year, with the annual reading at -$29.5 million for FY2025, 214.99% down from the prior year.
  • Net Cash Flow hit -$51.4 million in Q1 2026 for AbCellera Biologics, down from $44.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $247.0 million in Q2 2022 and bottomed at -$408.8 million in Q3 2022.
  • Average Net Cash Flow over 5 years is -$22.8 million, with a median of -$8.7 million recorded in 2025.
  • The largest annual shift saw Net Cash Flow surged 276.17% in 2024 before it crashed 2286.81% in 2026.
  • AbCellera Biologics' Net Cash Flow stood at $14.2 million in 2022, then plummeted by 382.92% to -$40.2 million in 2023, then soared by 179.28% to $31.8 million in 2024, then surged by 39.77% to $44.5 million in 2025, then crashed by 215.51% to -$51.4 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Net Cash Flow are -$51.4 million (Q1 2026), $44.5 million (Q4 2025), and -$8.7 million (Q3 2025).